Back to Search Start Over

Emtricitabine-induced pure red cell aplasia.

Authors :
Manickchund, Nithendra
du Plessis, Camille
John, Melanie-Anne A.
Manzini, Thandekile C.
Gosnell, Bernadett I.
Lessells, Richard J.
Moosa, Yunus S.
Source :
Southern African Journal of HIV Medicine. 2019, Vol. 20 Issue 1, p1-3. 3p.
Publication Year :
2019

Abstract

Introduction: Anemia is common in HIV. Parvo B19 infection is a well-recognised cause of red cell aplasia. Other causes of persistent pure red cell aplasia (PRCA) include anti-retroviral drugs such as zidovudine and lamivudine. We describe a case of PRCA that strongly implicates emtricitabine as the probable cause. Patient presentation: Patient was HIV positive and on treatment with a fixed drug combination consisting of tenofovir, emtricitabine and efavirenz for 3 months when she developed severe transfusion dependent anemia. The anemia, attributed to PRCA, was persistent and transfusion dependent for about one year. Management and outcome: Replacement of emtricitabine with abacavir resulted in a prompt, complete and lasting resolution of the anaemia, suggesting an etiologic role of emtricitabine in the PRCA. Conclusion: Emtricitibine is a rare cause of pure red cell aplasia. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16089693
Volume :
20
Issue :
1
Database :
Academic Search Index
Journal :
Southern African Journal of HIV Medicine
Publication Type :
Academic Journal
Accession number :
141255725
Full Text :
https://doi.org/10.4102/sajhivmed.v20i1.983